Abstract
A mere 9 years have passed since the revolutionary report describing the derivation of induced pluripotent stem cells from human fibroblasts and the first in-patient translational use of cells obtained from these stem cells has already been achieved. From the perspectives of clinicians and researchers alike, the promise of induced pluripotent stem cells is alluring if somewhat beguiling. It is now evident that this technology is nascent and many areas for refinement have been identified and need to be considered before induced pluripotent stem cells can be routinely used to stratify, treat and cure patients, and to faithfully model diseases for drug screening purposes. This review specifically addresses the pioneering approaches to improve induced pluripotent stem cell based models of nonischaemic cardiomyopathy.
| Original language | English |
|---|---|
| Article number | 4287158 |
| Journal | Stem Cells International |
| Volume | 2016 |
| DOIs | |
| Publication status | Published - 2016 |
Fingerprint
ASJC Scopus subject areas
- Cell Biology
- Molecular Biology
Cite this
Young at heart : Pioneering approaches to model nonischaemic cardiomyopathy with induced pluripotent stem cells. / Gowran, Aoife; Rasponi, Marco; Visone, Roberta; Nigro, Patrizia; Perrucci, Gianluca L.; Righetti, Stefano; Zanobini, Marco; Pompilio, Giulio.
In: Stem Cells International, Vol. 2016, 4287158, 2016.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Young at heart
T2 - Pioneering approaches to model nonischaemic cardiomyopathy with induced pluripotent stem cells
AU - Gowran, Aoife
AU - Rasponi, Marco
AU - Visone, Roberta
AU - Nigro, Patrizia
AU - Perrucci, Gianluca L.
AU - Righetti, Stefano
AU - Zanobini, Marco
AU - Pompilio, Giulio
PY - 2016
Y1 - 2016
N2 - A mere 9 years have passed since the revolutionary report describing the derivation of induced pluripotent stem cells from human fibroblasts and the first in-patient translational use of cells obtained from these stem cells has already been achieved. From the perspectives of clinicians and researchers alike, the promise of induced pluripotent stem cells is alluring if somewhat beguiling. It is now evident that this technology is nascent and many areas for refinement have been identified and need to be considered before induced pluripotent stem cells can be routinely used to stratify, treat and cure patients, and to faithfully model diseases for drug screening purposes. This review specifically addresses the pioneering approaches to improve induced pluripotent stem cell based models of nonischaemic cardiomyopathy.
AB - A mere 9 years have passed since the revolutionary report describing the derivation of induced pluripotent stem cells from human fibroblasts and the first in-patient translational use of cells obtained from these stem cells has already been achieved. From the perspectives of clinicians and researchers alike, the promise of induced pluripotent stem cells is alluring if somewhat beguiling. It is now evident that this technology is nascent and many areas for refinement have been identified and need to be considered before induced pluripotent stem cells can be routinely used to stratify, treat and cure patients, and to faithfully model diseases for drug screening purposes. This review specifically addresses the pioneering approaches to improve induced pluripotent stem cell based models of nonischaemic cardiomyopathy.
UR - http://www.scopus.com/inward/record.url?scp=84964829795&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964829795&partnerID=8YFLogxK
U2 - 10.1155/2016/4287158
DO - 10.1155/2016/4287158
M3 - Article
VL - 2016
JO - Stem Cells International
JF - Stem Cells International
SN - 1687-966X
M1 - 4287158
ER -